NVAX

#2093
Novavax, Inc. - Common Stock
11.0 9 USD
+7.46%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
10.89
11.19
Range Annuel
6.13
11.97
Changement quotidien
+7.46%
Changement Mensuel
+38.45%
Evolution sur 6 mois
+61.90%
Changement Annuel
+56.64%
Clôture Précédente
10.3 2
Open
10.9 4
Low
10.8 9
High
11.1 9
Volume
1 399
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques Dividendes
Trimestriel Annuel
  • Market Capitalization 1.82 B
  • Employee 749
  • Founded 1987
  • CEO John C. Jacobs
  • Website www.novavax.com
  • Headquarter Delaware, United States
  • FIGI BBG000NVSBL7
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
2.6
ratio cours/chiffre d'affaires
1.04

Novavax, Inc. - Common Stock

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

Nouvelles